• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13D/A filed by Senti Biosciences Inc.

    3/10/25 7:00:58 PM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SNTI alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)


    Senti Biosciences, Inc.

    (Name of Issuer)


    Common Stock, $0.0001 par value

    (Title of Class of Securities)


    81726A209

    (CUSIP Number)


    Stephanie Brecher
    New Enterprise Associates, 1954 Greenspring Drive, Suite 600
    Timonium, MD, 21093
    (410)842-4000

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    03/06/2025

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    SCHEDULE 13D

    CUSIP No.
    81726A209


    1 Name of reporting person

    New Enterprise Associates 15, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    3,775,615.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    3,775,615.00
    11Aggregate amount beneficially owned by each reporting person

    3,775,615.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    14.5 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    CUSIP No.
    81726A209


    1 Name of reporting person

    NEA Partners 15, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    3,775,615.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    3,775,615.00
    11Aggregate amount beneficially owned by each reporting person

    3,775,615.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    14.5 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    CUSIP No.
    81726A209


    1 Name of reporting person

    NEA 15 GP, LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    3,775,615.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    3,775,615.00
    11Aggregate amount beneficially owned by each reporting person

    3,775,615.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    14.5 %
    14Type of Reporting Person (See Instructions)

    OO



    SCHEDULE 13D

    CUSIP No.
    81726A209


    1 Name of reporting person

    Forest Baskett
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    3,775,615.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    3,775,615.00
    11Aggregate amount beneficially owned by each reporting person

    3,775,615.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    14.5 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    CUSIP No.
    81726A209


    1 Name of reporting person

    Anthony A. Florence, Jr.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    3,775,615.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    3,775,615.00
    11Aggregate amount beneficially owned by each reporting person

    3,775,615.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    14.5 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    CUSIP No.
    81726A209


    1 Name of reporting person

    Mohamad H. Makhzoumi
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    3,775,615.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    3,775,615.00
    11Aggregate amount beneficially owned by each reporting person

    3,775,615.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    14.5 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    CUSIP No.
    81726A209


    1 Name of reporting person

    Scott D. Sandell
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    3,775,615.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    3,775,615.00
    11Aggregate amount beneficially owned by each reporting person

    3,775,615.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    14.5 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Common Stock, $0.0001 par value
    (b)Name of Issuer:

    Senti Biosciences, Inc.
    (c)Address of Issuer's Principal Executive Offices:

    2 Corporate Drive, First Floor, South San Francisco, CALIFORNIA , 94080.
    Item 1 Comment:
    This Amendment No. 2 ("Amendment No, 2") to Schedule 13D amends and supplements the Schedule 13D originally filed on July 15, 2022 (the "Schedule 13D") and Amendment No. 1 thereto filed on December 4, 2024 ("Amendment No. 1"), relating to the Common Stock of the Issuer. Certain terms used but not defined in this Amendment No. 2 have the meanings assigned thereto in the Schedule 13D (and Amendment No. 1 thereto). Except as specifically provided herein, this Amendment No. 2 does not modify any of the information previously reported on the Schedule 13D (and Amendment No. 1 thereto).
    Item 2.Identity and Background
    (a)
    New Enterprise Associates 15, L.P. ("NEA 15"); NEA Partners 15, L.P. ("NEA Partners 15"), which is the sole general partner of NEA 15; and NEA 15 GP, LLC ("NEA 15 LLC" and together with NEA Partners 15, the "Control Entities"), which is the sole general partner of NEA Partners 15; and Forest Baskett ("Baskett"), Anthony A. Florence, Jr. ("Florence"), Mohamad H. Makhzoumi ("Makhzoumi") and Scott D. Sandell ("Sandell") (together, the "Managers"). The Managers are the managers of NEA 15 LLC. The persons named in this Item 2 are referred to individually herein as a "Reporting Person" and collectively as the "Reporting Persons."
    (b)
    The address of the principal business office of each Control Entity and Sandell is New Enterprise Associates, 1954 Greenspring Drive, Suite 600, Timonium, MD 21093. The address of the principal business office of Baskett and Makhzoumi is New Enterprise Associates, 2855 Sand Hill Road, Menlo Park, CA 94025. The address of the principal business office of Florence is New Enterprise Associates, 104 5th Avenue, 19th Floor, New York, NY 10011.
    (c)
    The principal business of NEA 15 is to invest in and assist growth-oriented businesses located principally in the United States. The principal business of NEA Partners 15 is to act as the sole general partner of NEA 15. The principal business of NEA 15 LLC is to act as the sole general partner of NEA Partners 15. The principal business of each of the Managers is to manage the Control Entities and a number of affiliated partnerships with similar businesses.
    (d)
    During the five years prior to the date hereof, none of the Reporting Persons has been convicted in a criminal proceeding or has been a party to a civil proceeding ending in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
    (e)
    During the five years prior to the date hereof, none of the Reporting Persons has been convicted in a criminal proceeding or has been a party to a civil proceeding ending in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
    (f)
    NEA 15 LLC is a limited liability company organized under the laws of the State of Delaware. NEA 15 and NEA Partners 15 are limited partnerships organized under the laws of the State of Delaware. Each of the Managers is a United States citizen.
    Item 3.Source and Amount of Funds or Other Consideration
     
    Not applicable.
    Item 4.Purpose of Transaction
     
    On March 6, 2025, the Issuer received Stockholder Approval for the previously reported Offering and on March 10, 2025, the Issuer exercised its right to automatically convert all shares of Series A Preferred Stock sold in the Offering into shares of Common Stock. NEA 15 acquired the NEA 15 Shares for investment purposes. Depending on market conditions, its continuing evaluation of the business and prospects of the Issuer and other factors, NEA 15 and other Reporting Persons may dispose of or acquire additional shares of the Issuer. Except as set forth above, none of the Reporting Persons has any present plans which relate to or would result in: (a) The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e) Any material change in the present capitalization or dividend policy of the Issuer; (f) Any other material change in the Issuer's business or corporate structure; (g) Changes in the Issuer's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person; (h) Causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (i) A class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934; or (j) Any action similar to any of those enumerated above.
    Item 5.Interest in Securities of the Issuer
    (a)
    NEA 15 is the record owner of 3,775,615 shares of Common Stock (the "NEA 15 Shares"). As the general partner of NEA 15, NEA Partners 15 may be deemed to own beneficially the NEA 15 Shares. As the sole general partner of NEA Partners 15, NEA 15 LLC may be deemed to own beneficially the NEA 15 Shares. As members of NEA 15 LLC, each of the Managers may be deemed to own beneficially the NEA 15 Shares. Each Reporting Person disclaims beneficial ownership of the NEA 15 Shares other than those shares which such person owns of record. The percentage of outstanding Common Stock of the Issuer which may be deemed to be beneficially owned by each Reporting Person is set forth on Line 13 of such Reporting Person's cover sheet. Such percentage was calculated based on (a) 4,829,457 shares of Common Stock reported by the Issuer to be outstanding as of January 21, 2025, on the Issuer's Definitive Proxy Statement filed with the SEC on January 27, 2025 and (b) 21,157,000 shares of Common Stock issued in connection with the automatic conversion of the Series A Preferred Stock sold pursuant to the Offering.
    (b)
    Regarding the number of shares as to which such person has: (i) sole power to vote or to direct the vote: See line 7 of cover sheets (ii) shared power to vote or to direct the vote: See line 8 of cover sheets (iii) sole power to dispose or to direct the disposition: See line 9 of cover sheets (iv) shared power to dispose or to direct the disposition: See line 10 of cover sheets.
    (c)
    None of the Reporting Persons has effected any transaction in the NEA 15 Shares during the last 60 days.
    (d)
    No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, NEA 15 Shares beneficially owned by any of the Reporting Persons.
    (e)
    Not applicable.
    Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
     
    Not applicable.
    Item 7.Material to be Filed as Exhibits.
     
    Exhibit 1 - Agreement regarding filing of joint Schedule 13D. Exhibit 2 - Power of Attorney regarding filings under the Securities Exchange Act of 1934, as amended.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    New Enterprise Associates 15, L.P.
     
    Signature:/s/ Zachary Bambach
    Name/Title:Zachary Bambach as attorney-in-fact for Anthony A. Florence Jr., Managing Partner and Co-Chief Executive Officer
    Date:03/10/2025
     
    Signature:/s/ Zachary Bambach
    Name/Title:Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi, Managing Partner and Co-Chief Executive Officer
    Date:03/10/2025
     
    NEA Partners 15, L.P.
     
    Signature:/s/ Zachary Bambach
    Name/Title:Zachary Bambach as attorney-in-fact for Anthony A. Florence Jr., Managing Partner and Co-Chief Executive Officer
    Date:03/10/2025
     
    Signature:/s/ Zachary Bambach
    Name/Title:Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi, Managing Partner and Co-Chief Executive Officer
    Date:03/10/2025
     
    NEA 15 GP, LLC
     
    Signature:/s/ Zachary Bambach
    Name/Title:Zachary Bambach as attorney-in-fact for Anthony A. Florence Jr., Managing Partner and Co-Chief Executive Officer
    Date:03/10/2025
     
    Signature:/s/ Zachary Bambach
    Name/Title:Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi, Managing Partner and Co-Chief Executive Officer
    Date:03/10/2025
     
    Forest Baskett
     
    Signature:/s/ Zachary Bambach
    Name/Title:Zachary Bambach as attorney-in-fact for Forest Baskett
    Date:03/10/2025
     
    Anthony A. Florence, Jr.
     
    Signature:/s/ Zachary Bambach
    Name/Title:Zachary Bambach as attorney-in-fact for Anthony A. Florence Jr.
    Date:03/10/2025
     
    Mohamad H. Makhzoumi
     
    Signature:/s/ Zachary Bambach
    Name/Title:Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi
    Date:03/10/2025
     
    Scott D. Sandell
     
    Signature:/s/ Zachary Bambach
    Name/Title:Zachary Bambach as attorney-in-fact for Scott D. Sandell
    Date:03/10/2025
    Comments accompanying signature:
    This Amendment No. 2 to Schedule 13D was executed by Zachary Bambach on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which is attached as Exhibit 2.
    Get the next $SNTI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SNTI

    DatePrice TargetRatingAnalyst
    10/14/2025$12.00Buy
    H.C. Wainwright
    6/6/2025$5.00Buy
    Laidlaw
    10/7/2022$7.50Equal-Weight
    Morgan Stanley
    More analyst ratings

    $SNTI
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by Senti Biosciences Inc.

    SCHEDULE 13D/A - Senti Biosciences, Inc. (0001854270) (Subject)

    1/20/26 4:05:54 PM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Senti Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Senti Biosciences, Inc. (0001854270) (Filer)

    12/9/25 7:04:36 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Senti Biosciences Inc.

    10-Q - Senti Biosciences, Inc. (0001854270) (Filer)

    11/13/25 5:09:56 PM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SNTI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Senti Biosciences Selected for On-Stage Presentation at Healthcare Conference Taipei 2026

    SOUTH SAN FRANCISCO, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D., Co-Founder and Chief Executive Officer of Senti, has been selected to deliver an on-stage company presentation at the Healthcare Conference Taipei 2026, co-hosted by J.P. Morgan, UC Berkeley, and the Regent Taipei happening February 10–11, 2026, at the Regent Taipei Hotel. Senti's presentation will be held on Tuesday, February 10, 2026, from 10:30 AM to 10:40 AM local time, in Track 1 at the Reg

    2/3/26 9:00:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Senti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company's Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT Designation

    Access the segment here SOUTH SAN FRANCISCO, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it participated in a Virtual Investor CEO Connect Segment. As part of the segment, Timothy Lu, MD, PhD, CEO of Senti, discussed its recent news release announcing that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to SENTI-202, the Company's potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (C

    1/14/26 9:15:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Senti Bio to Participate in Panel Presentation at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Dr. Timothy Lu, Co-Founder and CEO, will participate as a panelist alongside Jonah Comstock, Editor in Chief, pharmaphorum; Jay Hartenbach, President & COO, Diakonos Oncology; George Magrath CEO, Opus Genetics; Kate Rochlin COO, IN8bio; and Amber Salzman CEO, Epicrispr Biotechnologies at Biotech Showcase 2026, taking place January 12–14, 2026, in San Francisco, CA. Panel presentation details are as follows: Title: Enginee

    1/9/26 8:55:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SNTI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Pres. & Chief Med. & Dev. Off. Rajangam Kanya covered exercise/tax liability with 1,384 shares (SEC Form 4)

    4 - Senti Biosciences, Inc. (0001854270) (Issuer)

    2/3/26 4:17:23 PM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CEO Lu Timothy K covered exercise/tax liability with 4,191 shares, decreasing direct ownership by 0.58% to 720,249 units (SEC Form 4)

    4 - Senti Biosciences, Inc. (0001854270) (Issuer)

    2/3/26 4:16:46 PM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Baum Bryan Daniel

    4 - Senti Biosciences, Inc. (0001854270) (Issuer)

    7/21/25 5:56:55 PM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SNTI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Senti Bio with a new price target

    H.C. Wainwright initiated coverage of Senti Bio with a rating of Buy and set a new price target of $12.00

    10/14/25 8:53:29 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Laidlaw initiated coverage on Senti Bio with a new price target

    Laidlaw initiated coverage of Senti Bio with a rating of Buy and set a new price target of $5.00

    6/6/25 8:36:59 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Morgan Stanley initiated coverage on Senti Bio with a new price target

    Morgan Stanley initiated coverage of Senti Bio with a rating of Equal-Weight and set a new price target of $7.50

    10/7/22 7:14:34 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SNTI
    Leadership Updates

    Live Leadership Updates

    View All

    Senti Bio Bolsters Scientific Advisory Board with Appointment of James B. Trager, Ph.D.

    Industry leader in the development and application of cellular therapies, including CAR NK products, for cancer Led development of multiple clinical candidates from conception through IND and early clinical development Vast experience in technology licensing, correlation from "bench to bedside" and back and execution of scientific strategy SOUTH SAN FRANCISCO, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced the appointment of James B. Trager, Ph.D. to its Scientific Advisor

    4/10/25 8:45:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SNTI
    Financials

    Live finance-specific insights

    View All

    Senti Biosciences Selected for On-Stage Presentation at Healthcare Conference Taipei 2026

    SOUTH SAN FRANCISCO, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D., Co-Founder and Chief Executive Officer of Senti, has been selected to deliver an on-stage company presentation at the Healthcare Conference Taipei 2026, co-hosted by J.P. Morgan, UC Berkeley, and the Regent Taipei happening February 10–11, 2026, at the Regent Taipei Hotel. Senti's presentation will be held on Tuesday, February 10, 2026, from 10:30 AM to 10:40 AM local time, in Track 1 at the Reg

    2/3/26 9:00:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Senti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company's Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT Designation

    Access the segment here SOUTH SAN FRANCISCO, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it participated in a Virtual Investor CEO Connect Segment. As part of the segment, Timothy Lu, MD, PhD, CEO of Senti, discussed its recent news release announcing that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to SENTI-202, the Company's potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (C

    1/14/26 9:15:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Senti Bio to Participate in Panel Presentation at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Dr. Timothy Lu, Co-Founder and CEO, will participate as a panelist alongside Jonah Comstock, Editor in Chief, pharmaphorum; Jay Hartenbach, President & COO, Diakonos Oncology; George Magrath CEO, Opus Genetics; Kate Rochlin COO, IN8bio; and Amber Salzman CEO, Epicrispr Biotechnologies at Biotech Showcase 2026, taking place January 12–14, 2026, in San Francisco, CA. Panel presentation details are as follows: Title: Enginee

    1/9/26 8:55:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SNTI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Senti Biosciences Inc.

    SC 13D/A - Senti Biosciences, Inc. (0001854270) (Subject)

    12/4/24 7:08:03 PM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Senti Biosciences Inc.

    SC 13G - Senti Biosciences, Inc. (0001854270) (Subject)

    2/14/23 12:38:17 PM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Senti Biosciences Inc. (Amendment)

    SC 13G/A - Senti Biosciences, Inc. (0001854270) (Subject)

    2/14/23 11:52:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care